---
figid: PMC9077075__ajcr0012-1686-f3
pmcid: PMC9077075
image_filename: ajcr0012-1686-f3.jpg
figure_link: /pmc/articles/PMC9077075/figure/fig03/
number: Figure 3
figure_title: ''
caption: Effects of anti-tumor drugs on stemness markers expression and cell proliferation
  of tumor cell lines and their tumorspheres (TS) by flow cytometric analysis. A.
  Percentages of CD117, ALDH1, CD117/ALDH1-expressing ES2, ES2TR160, ES2 TS, and ES2TR160
  (TS) treated with or without paclitaxel by flow cytometric analysis. B. Percentages
  of AC133 expression of ES2 or ES2TR160 and their tumorspheres treated with 10 μM
  5-aza-dC (5AZA) and/or IC50 of RAD001 by flowcytometric analysis. (*P<0.05, **P<0.01,
  ***P<0.001, all by students’ t-test).
article_title: Everolimus combined with 5-aza-2-deoxycytidine generated potent anti-tumor
  effects on ovarian clear cell cancer stem-like/spheroid cells by inhibiting the
  COL6A3-AKT-mTOR pathway.
citation: Chih-Ming Ho, et al. Am J Cancer Res. 2022;12(4):1686-1706.
year: '2022'

doi: ''
journal_title: American Journal of Cancer Research
journal_nlm_ta: Am J Cancer Res
publisher_name: e-Century Publishing Corporation

keywords:
- 5-aza-2-deoxycytidine
- everolimus
- ovarian cancer
- ovarian clear cell
- cancer stem cells
- COL6A3-AKT-mTOR pathway

---
